• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.

    5/27/26 7:42:47 PM ET
    $FLGT
    Medical Specialities
    Health Care
    Get the next $FLGT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)


    Fulgent Genetics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    359664109

    (CUSIP Number)
    Ming Hsieh
    c/o Fulgent Genetics, Inc., 4399 Santa Anita Avenue
    El Monte, CA, 91731
    (626) 350-0537


    Scott M. Stanton, Esq.
    c/o Mintz, 3580 Carmel Mountain Road, Suite 300
    San Diego, CA, 92130
    (858) 314-1500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/22/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    359664109


    1 Name of reporting person

    Ming Hsieh
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    8,650,723.00
    8Shared Voting Power

    221,816.00
    9Sole Dispositive Power

    8,650,723.00
    10Shared Dispositive Power

    221,816.00
    11Aggregate amount beneficially owned by each reporting person

    8,872,539.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    32.26 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    In reference to Row 4 above, the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Fulgent Genetics, Inc. (the "Issuer") acquired by Ming Hsieh (the "Reporting Person") since the Reporting Person's last amendment to this Schedule 13D were acquired through equity award vestings in connection with the Reporting Person's services as Chief Executive Officer of the Issuer. No cash consideration was paid by the Reporting Person in connection with these acquisitions. See Item 3 of this Schedule 13D for additional information. In reference to Rows 7 and 9 above, sole voting and dispositive power consists of (i) 7,895,115 shares of Common Stock of the Issuer held of record by The Ming Hsieh Trust (the "Trust"), of which Mr. Hsieh possesses sole voting and dispositive power as the trustee, of which 1,000,000 shares of Common Stock of the Issuer are pledged as security pursuant to a pre-paid forward arrangement as disclosed on that certain Form 4 filed by the Reporting Person with the U.S. Securities and Exchange Commission (the "SEC") on March 12, 2024, and 5,760,733 shares of Common Stock are pledged as collateral account for a credit facility, (ii) 746,423 shares of Common Stock of the Issuer held of record by Mr. Hsieh, (iii) 1,000 shares of Common Stock of the Issuer held of record by a minor child under a Uniform Transfers to Minors Act account, of which Mr. Hsieh possesses sole voting and dispositive power as the sole custodian of the account, and (iv) 8,185 shares of Common Stock of the Issuer subject to Restricted Stock Unit awards granted to Mr. Hsieh that will vest or settle within 60 days after May 27, 2026. This 8,185 shares of Common Stock presumes no shares are withheld for the purposes of withholding taxes. In reference to Rows 8 and 10 above, shared voting and dispositive power consists of (i) 220,816 shares of Common Stock of the Issuer held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, serve on the investment committee of the Dynasty Trust and (ii) 1,000 shares of Common Stock of the Issuer held by an immediate family member of Mr. Hsieh residing in the same household which were previously held in a custodial account under the Uniform Transfers to Minors Act, over which Mr. Hsieh served as sole custodian, and were transferred to this immediate family member upon this individual reaching the age of majority. Mr. Hsieh may be deemed to share voting and dispositive power over these 1,000 shares by virtue of this family member's residence in his household. Mr. Hsieh disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. In reference to Row 13 above, the percent of class represented by amount in Row 11 was calculated based on 27,493,435 shares of Common Stock of the Issuer issued and outstanding as of May 22, 2026, based on information provided to the Reporting Person by the Issuer.


    SCHEDULE 13D

    CUSIP Number(s):
    359664109


    1 Name of reporting person

    The Ming Hsieh Trust
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    7,895,115.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    7,895,115.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    7,895,115.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    28.72 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    In reference to Row 4 above, the Trust has not acquired any shares of Common Stock since the Reporting Person's last amendment to this Schedule 13D. All shares of Common Stock currently held by the Trust were acquired through transfers from the Reporting Person as previously reported. See Item 3 of Amendment No. 4 to Schedule 13D previously filed with the SEC on March 31, 2026, for additional information. In reference to Rows 7 and 9 above, sole voting and dispositive power consists of 7,895,115 shares of Common Stock of the Issuer held of record by the Trust, over which the Reporting Person possesses sole voting and dispositive power as the trustee of the Trust. In reference to Row 13 above, the percent of class represented by amount in Row 11 was calculated based on 27,493,435 shares of Common Stock of the Issuer issued and outstanding as of May 22, 2026, based on information provided to the Reporting Person by the Issuer.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    Fulgent Genetics, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    4399 Santa Anita Avenue, El Monte, CALIFORNIA , 91731.
    Item 1 Comment:
    This amendment No. 5 to Schedule 13D (this "Statement") relates to the common stock, par value $0.0001 per share (the "Common Stock"), of Fulgent Genetics, Inc., a Delaware corporation (the "Issuer"). The principal executive office of the Issuer is located at 4399 Santa Anita Avenue, El Monte, California 91731. Except as expressly amended herein, this Statement supplements Amendment No. 4 to Schedule 13D previously filed with the SEC on March 31, 2026.
    Item 2.Identity and Background
    (a)
    This Statement is being filed by Ming Hsieh, (the "Reporting Person") and by the Reporting Person on behalf of The Ming Hsieh Trust (the "Trust").
    (b)
    The business address of the Reporting Person and the Trust is c/o Fulgent Genetics, Inc., 4399 Santa Anita Avenue, El Monte, California 91731.
    (c)
    The Reporting Person serves as Chief Executive Officer and Chairperson of the Board of Directors (the "Board") of the Issuer. The Trust was formed for personal estate planning purposes.
    (d)
    During the last five years, neither the Reporting Person nor the Trust has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, neither the Reporting Person nor the Trust has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    The Reporting Person is a citizen of the United States of America. The Trust is organized in the State of California.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Since the filing of Amendment No. 4 to this Schedule 13D, the Reporting Person acquired shares of Common Stock solely upon the vesting of equity awards previously granted under the Issuer's equity incentive plans as described below. No cash consideration was paid for the acquisition of shares of Common Stock since the filing of Amendment No. 4 to this Schedule 13. On May 26, 2026, 5,496 shares of Common Stock vested pursuant to issued and outstanding RSUs. 2,949 shares of Common Stock were withheld for the payment of withholding taxes.
    Item 4.Purpose of Transaction
     
    The Reporting Person holds the shares of Common Stock reported in this Statement for general investment purposes. The Reporting Person may, from time to time, acquire additional, or dispose of, shares of Common Stock or other securities of the Issuer, in the Reporting Person's capacity as Chief Executive Officer and Chairperson of the Board of the Issuer or otherwise, or engage in discussions with the Issuer concerning investments in the Issuer. The Reporting Person intends to review his ownership of Common Stock (including shares of Common Stock held through the Trust) on a continuing basis and, depending upon the price and availability of shares of Common Stock of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Person, general stock market and economic conditions, tax considerations and other factors considered relevant, the Reporting Person may decide at any time to increase or to decrease the size of his holdings of the Issuer's securities or securities derived of, exercisable for or convertible into the Issuer's securities.
    Item 5.Interest in Securities of the Issuer
    (a)
    The Reporting Person beneficially owns 8,872,539 shares of Common Stock of the Issuer, representing 32.26% of all of the issued and outstanding shares of Common Stock of the Issuer. The Trust beneficially owns 7,895,115 shares of Common Stock of the Issuer, representing 28.72% of all of the issued and outstanding shares of Common Stock of the Issuer. The percentages set forth in this Item 5(a) are based on 27,493,435 shares of Common Stock issued and outstanding as of May 22, 2026, based on information provided to the Reporting Person by the Issuer.
    (b)
    The Reporting Person has the sole power to vote or direct the vote and dispose or direct the disposition of 8,650,723 shares of Common Stock of the Issuer (which includes the shares of Common Stock held by the Trust) as of and within sixty (60) days after May 27, 2026. The Reporting Person has shared power to vote or direct the vote or dispose or direct the disposition of 221,816 shares of Common Stock as of and within 60 days of May 27, 2026. The Reporting Person is a member of the investment committee of the Dynasty Trust and, as such, shares voting and dispositive power over the shares held by the Dynasty Trust.
    (c)
    The transactions effected by the Reporting Person in the 60 days prior to the filing of this Statement are set forth in Item 3 of this Statement. Except as set forth in Item 3 of this Statement, no other transactions in the shares of Common Stock of the Issuer have been effected by the Reporting Person during the 60-day period prior to the filing of this Statement.
    (d)
    Not applicable.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    1,000,000 shares of Common Stock of the Trust are pledged as security pursuant to a pre-paid forward arrangement as disclosed on that certain Form 4 filed by the Reporting Person with the SEC on March 12, 2024, and 5,760,733 shares of Common Stock of the Trust are pledged as collateral for a credit facility provided to the Trust by The Charles Schwab Corporation. This arrangement is subject to customary terms which provide that, in the event of a default, the lender may be entitled to dispose of the pledged shares. The Reporting Person and his spouse, Eva Hsieh, are members of the investment committee of the Dynasty Trust. See Item 5(b) of this Statement. Except as described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 of this Statement and between such persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1: Joint Filing Agreement, dated as of December 22, 2020, by and among Mr. Hsieh and the Trust (incorporated by reference to Exhibit 1 of that certain Schedule 13D/A filed with the SEC on December 22, 2020). https://www.sec.gov/Archives/edgar/data/1674930/000156459020058063/none-sc13d.htm

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ming Hsieh
     
    Signature:/s/ Ming Hsieh
    Name/Title:Ming Hsieh
    Date:05/27/2026
     
    The Ming Hsieh Trust
     
    Signature:/s/ Ming Hsieh
    Name/Title:By: Ming Hsieh, Trustee
    Date:05/27/2026
    Get the next $FLGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGT

    DatePrice TargetRatingAnalyst
    8/5/2025$30.00Neutral → Buy
    UBS
    12/7/2023$35.00Neutral
    UBS
    12/8/2022$65.00 → $40.00Overweight → Neutral
    Piper Sandler
    11/18/2022$45.00Outperform
    Raymond James
    8/25/2022$65.00Outperform
    Credit Suisse
    2/4/2022$80.00Overweight
    Piper Sandler
    1/25/2022$141.00 → $125.00Outperform
    Oppenheimer
    8/10/2021$55.00 → $65.00Underperform
    Credit Suisse
    More analyst ratings

    $FLGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Kim Paul bought $1,596,470 worth of shares (100,000 units at $15.96), increasing direct ownership by 40% to 348,282 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    3/5/25 6:47:40 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulgent Presents Updated FID-007 Data at ASCO 2026

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020," will present updated preliminary data from the Company's open-label, randomized Phase 2 study (NCT0633

    6/1/26 7:00:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in Hall D1 of McCormick Place, Chicago. The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020". It presents interim data from th

    5/21/26 5:03:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

    New solution helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care FoundationOne PGx includes genes associated with the metabolism of medicines that have strong clinical evidence and actionable guidelines, including DPYD Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch FoundationOne®PGx, a pharmacogenetic (PGx) offering to identify genetic differences that influence how medicines are metabolized and processed by the body. FoundationOne PGx will be offered in the United States through a partnership with Fulgent Genetics, Inc. (NASDAQ:FLGT) and will be available to order thro

    5/4/26 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    6/3/26 5:29:54 PM ET
    $FLGT
    Medical Specialities
    Health Care

    CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    6/3/26 5:29:45 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Chief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    6/3/26 5:29:37 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.

    SCHEDULE 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    5/27/26 7:42:47 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Genetics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Fulgent Genetics, Inc. (0001674930) (Filer)

    5/21/26 5:04:12 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Fulgent Genetics Inc.

    S-8 - Fulgent Genetics, Inc. (0001674930) (Filer)

    5/14/26 4:59:48 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fulgent Genetics upgraded by UBS with a new price target

    UBS upgraded Fulgent Genetics from Neutral to Buy and set a new price target of $30.00

    8/5/25 7:03:39 AM ET
    $FLGT
    Medical Specialities
    Health Care

    UBS initiated coverage on Fulgent Genetics with a new price target

    UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00

    12/7/23 6:19:41 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Genetics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously

    12/8/22 7:45:09 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Financials

    Live finance-specific insights

    View All

    Fulgent Reports First Quarter 2026 Financial Results

    Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-GAAP gross margin of 32.3% GAAP loss of $24.8 million, or $(0.80) per share; Non-GAAP loss of $11.0 million, or $(0.36) per share Ended the first quarter of 2026 with $604.7 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106 million Fulgent Genetics, In

    5/1/26 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a

    4/16/26 7:30:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ($0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share Ended the year with $705.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.3 million Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announce

    2/27/26 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

    SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    11/5/24 4:46:55 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

    SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    1/23/24 4:13:58 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

    SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    1/26/23 8:52:11 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Leadership Updates

    Live Leadership Updates

    View All

    Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

    Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics ("Bako"), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of approximately $55.5 m

    12/22/25 4:10:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

    PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year

    6/10/24 1:00:00 AM ET
    $FLGT
    $NEO
    Medical Specialities
    Health Care
    Precision Instruments